Beta2-agonists for chronic obstructive pulmonary disease (COPD)

References

Citations

1. Kerstjens H, et al. (2005). Chronic obstructive pulmonary disease. Clinical Evidence (13): 1923-1947.

2. Stoller JK (2002). Acute exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine, 346(13): 987–994.

3. Calverley P, et al. (2003). Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet, 361: 449–456.

4. Hanania NA, et al. (2003). The efficacy and safety of fluticasone propionate (250 micrograms)/salmeterol (50 micrograms) combined in the Diskus Inhaler for the treatment of COPD. Chest, 124: 834–843.

5. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2005). Executive summary (updated 2005). In Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available online: http://www.goldcopd.com/GuidelinesResources.asp?I1=2&I2=0.

6. Health Canada (2005). Advisory: Safety information about a class of asthma drugs known as long-acting beta-2 agonists. Available online: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2005/2005_107_e.html.

Author:	Douglas Dana Robin Parks, MS	Last Updated: August 28, 2006
Medical Review:	Renée M. Crichlow, MD - Family Medicine Tom Bailey, MD - Family Medicine Ken Y. Yoneda, MD - Pulmonology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.